Selective digestive tract decontamination decreases time on ventilator in guillain-barré syndrome

Neurocritical Care

Volumn 15, Issue 1, 2011, Pages 128-133

  Eyssen, Martine E Bos ^a   Van Doorn, Pieter A ^a   Jacobs, Bart C ^a   Steyerberg, Ewout W ^a   Van Der Voort, Peter H J ^b   Zandstra, Durk F ^b   Horn, Janneke ^c   Spronk, Peter E ^d   Hoedemaekers, Cornelia W ^e   Bakker, Jan ^a   Van Der Jagt, Mathieu ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d GELRE HOSPITALS   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Guillain Barr syndrome; Mechanical ventilation; Prognosis; SDD; Ventilator associated pneumonia

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; GUILLAIN BARRE SYNDROME; HUMAN; INFECTION PREVENTION; INTENSIVE CARE UNIT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NETHERLANDS; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SELECTIVE DECONTAMINATION OF DIGESTIVE TRACT; THERAPY; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; ANTI-BACTERIAL AGENTS; DECONTAMINATION; FEMALE; GASTROINTESTINAL TRACT; GUILLAIN-BARRE SYNDROME; HUMANS; INTENSIVE CARE; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052639743     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-011-9536-5     Document Type: Article

References (22)

1. Dhar R, Stitt L, Hahn AF. The morbidity and outcome of patients with Guillain-Barré syndrome admitted to the intensive care unit. J Neurol Sci. 2008;264:121-8. (Pubitemid 350184084)
2. Orlikowski D, Sharshar T, Porcher R, Annane D, Raphael JC, Clair B. Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain-Barré syndrome. Intensive Care Med. 2006;32:1962-9. (Pubitemid 44833109)
3. Ali MI, Fernández-Pérez ER, Pendem S, Brown DR, Wijdicks EF, Gajic O. Mechanical ventilation in patients with Guillain- Barré syndrome. Respir Care. 2006;51:1403-7.
4. Tejerina E, Frutos-Vivar F, Restrepo MI, et al. Incidence, risk factors, and outcome of ventilator-associated pneumonia, International Mechanical Ventilation Study Group. J Crit Care. 2006; 21:56-65.
5. De Jonge E, Schultz MJ, Spanjaard L, et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: A randomised controlled trial. Lancet. 2003;362:1011-6. (Pubitemid 37186877)
6. De Smet AM, Kluytmans JA, Cooper BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med. 2009;360:20-31.
7. Du Moulin GC, Paterson G, Hedley Whyte J, Lisbon A. Aspiration of gastric bacteria in antacid-treated patients: A frequent cause of post-operative colonization of the airway. Lancet. 1982;1:242-5. (Pubitemid 12205279)
8. Ruts L, Drenthen J, Jacobs BC, van Doorn PA, Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain- Barré syndrome: A prospective study. Neurology. 2010;74: 1680-6.
9. Van der Jagt M. Intensive care unit-acquired weakness. Crit Care Med. 2010;38:1617-9.
10. Van Doorn PA, Schmitz PI, Ang CW, Van der Meché FG, Van Koningsveld R. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology. 2000;54: 620-5. (Pubitemid 30082928)
11. Kuitwaard K, Bos Eyssen ME, Blomkwist-Markens PH, Van Doorn PA. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst. 2009;14:310-5.
12. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997;349:225-230.
13. Van Koningsveld R, Schmitz PI, Meché FG, Visser LH, Meulstee J, van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain- Barré syndrome: Randomised trial. Dutch GBS study group. Lancet. 2004;363:192-6. (Pubitemid 38114716)
14. Van der Meché FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain- Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992;326:1123-9.
15. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27: S21-4. (Pubitemid 20178648)
16. Van Koningsveld R, Steyerberg EW, Hughes RAC, Swan AV, Van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol. 2007;6:589-94. (Pubitemid 46921042)
17. Hughes RAC, Newsom-Davis J, Perkin GD, Perce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet. 1978;2:750-3. (Pubitemid 9034500)
18. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010;67: 781-7.
19. Liberati A, D'Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev. 2009;7:CD000022.
20. Henderson RD, Lawn ND, Fletcher DD, McClelland RL, Wijdicks EF. The morbidity of Guillain-Barré syndrome admitted to the intensive care unit. Neurology. 2003;60:17-21. (Pubitemid 36070637)
21. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barré syndrome: Incidence and mortality rates in US hospitals. Neurology. 2008;70:1608-13. (Pubitemid 351620316)
22. Chiò A, Cocito D, Leone M, et al. Guillain-Barré syndrome: A prospective, population-based incidence and outcome survey. Register for Guillain-Barré Syndrome. Neurology. 2003;60: 1146-50. (Pubitemid 36418776)